Clinical Trials Browser

Phase 1/2 × AML × Clear all

NCT02418000 2019-03-20

A Study of E6201 for the Treatment of Advanced Hematologic Malignancies With FLT3 and/or Ras Mutations

Phase 1/2 Terminated

27 enrolled 32 charts

AML